EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H’28 ...
VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the initiation of cell line development for ...
FGFs are established as key players during neural induction and also during the induction of ectodermal placodes and possibly the neural crest. FGFs are utilised in the posteriorization of the neural ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results